secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-07-09T20:09:51+00:00
Accession:  0001549595-26-000038
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix enters $2.3B Roche collaboration for bexobrutideg; Q2 net loss $89.5M
---------------------------------------------------------------------------

- Global collaboration with Roche for bexobrutideg: $700M upfront, up to $2.3B total; co-dev/co-commercialization in hematology, immunology, neurology.
- Q2 FY2026 revenue $9.0M (down from $44.1M YoY); net loss $89.5M ($0.81/share) vs $43.5M loss prior year.
- Cash, equivalents & marketable securities $443.5M as of May 31, 2026; pro-forma ~$1.14B including expected $700M Roche payment.
- Bexobrutideg Phase 1a/1b CLL data: ORR 83% (Phase 1a) and 92.9% (Phase 1b Cohort 5); median PFS 22.1 months.
- Enrollment continues in pivotal Phase 2 DAYBreak CLL-201; Phase 3 vs pirtobrutinib expected to start mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/0001549595-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer